Ulf Wiinberg - UCB SA Independent Director
UCBJY Stock | USD 58.22 1.22 2.14% |
Director
Mr. Ulf Wiinberg has served as Independent NonExecutive Director of UCB S.A. since April 28, 2016. He is Member of the Audit Committee of the Company . He is a pharmaceutical industry professional. He started as a sales representative at Lederle Laboratories in Sweden, which later was acquired by Wyeth. At Wyeth, he was President of the global consumer health care business, and later President for the European business and strategically responsible for biotechnology and vaccines. He served as a member of the management committee from 20022008. From 2008 to end of 2014, he was the CEO of Lundbeck, a Danish company focusing on brain diseases. During his career, he has worked on development and in production of pharmaceutical products and vaccines that can make a big difference for patients. He has also served on the boards of the industry associations for the pharmaceutical and consumer healthcare business, Pharma, Efpia and WSMI. He was Chairman of the Board of Hansa Medical, Board member at Alfa Laval and Board member at Agenus. since 2016.
Age | 59 |
Tenure | 8 years |
Phone | 32 2 559 99 99 |
Web | https://www.ucb.com |
Ulf Wiinberg Latest Insider Activity
Tracking and analyzing the buying and selling activities of Ulf Wiinberg against UCB SA pink sheet is an integral part of due diligence when investing in UCB SA. Ulf Wiinberg insider activity provides valuable insight into whether UCB SA is net buyers or sellers over its current business cycle. Note, UCB SA insiders must abide by specific rules, including filing SEC forms every time they buy or sell UCB SA'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Ulf Wiinberg over three months ago Purchase by Ulf Wiinberg of 25000 shares of Agenus | ||
Ulf Wiinberg over three months ago Acquisition by Ulf Wiinberg of 18001 shares of Agenus subject to Rule 16b-3 | ||
Ulf Wiinberg over six months ago Acquisition by Ulf Wiinberg of 16018 shares of Agenus subject to Rule 16b-3 | ||
Ulf Wiinberg over six months ago Acquisition by Ulf Wiinberg of 11901 shares of Agenus subject to Rule 16b-3 |
UCB SA Management Efficiency
The company has return on total asset (ROA) of 0.0468 % which means that it generated a profit of $0.0468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1069 %, meaning that it generated $0.1069 on every $100 dollars invested by stockholders. UCB SA's management efficiency ratios could be used to measure how well UCB SA manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
Kasim Kutay | Novo Nordisk AS | 55 | |
Thomas Rantzau | Novo Nordisk AS | 46 | |
Liz Hewitt | Novo Nordisk AS | 64 | |
Christine Poon | Regeneron Pharmaceuticals | 65 | |
Joseph Goldstein | Regeneron Pharmaceuticals | 77 | |
Thomas Koestler | Novo Nordisk AS | 63 | |
Bonnie Bassler | Regeneron Pharmaceuticals | 55 | |
Elizabeth Corley | Pearson PLC ADR | 63 | |
David Altshuler | Vertex Pharmaceuticals | 53 | |
Sally Johnson | Pearson PLC ADR | 51 | |
Soeren Pedersen | Novo Nordisk AS | 52 | |
Joshua Lewis | Pearson PLC ADR | 53 | |
Sylvie Gregoire | Novo Nordisk AS | 59 | |
George Sing | Regeneron Pharmaceuticals | 68 | |
Eivind Kolding | Novo Nordisk AS | 55 | |
Vivienne Cox | Pearson PLC ADR | 60 | |
Mary Szela | Novo Nordisk AS | 52 | |
David Greenway | Vertex Pharmaceuticals | 34 | |
Terrence Kearney | Vertex Pharmaceuticals | 63 | |
Nancy Phelan | Moderna | 48 | |
Stefan Loren | Moderna | 50 |
Management Performance
Return On Equity | 0.11 | |||
Return On Asset | 0.0468 |
UCB SA ADR Leadership Team
Elected by the shareholders, the UCB SA's board of directors comprises two types of representatives: UCB SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of UCB. The board's role is to monitor UCB SA's management team and ensure that shareholders' interests are well served. UCB SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, UCB SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
Pascale Richetta, Executive Vice President Bone Patient Value Unit Head, Member of the Executive Committee | ||
Detlef Thielgen, CFO and Executive VP | ||
Kay Davies, Independent Director | ||
Dirk Teuwen, VP Corporate Societal Responsibility | ||
Anna Richo, Executive VP and General Counsel | ||
Viviane Monges, Independent Non-Executive Director | ||
Gerhard Mayr, Non-Executive Chairman of the Board | ||
Cyril Janssen, Director | ||
Caroline Vancoillie, Chief Functions | ||
Cedric Rijckevorsel, Director | ||
JeanChristophe Tellier, Chairman of the Executive Committee, CEO | ||
Arnoud Calesberg, Non-Executive Director | ||
Mark McDade, COO and Executive VP | ||
Xavier Michel, Vice President and Secretary General | ||
Dhavalkumar Patel, Executive Vice President Chief Scientific Officer, Member of the Executive Committee | ||
Bharat Tewarie, Executive Vice President Chief Marketing Officer | ||
Roch Doliveux, Chairman of the Executive Committee, CEO, Executive Director | ||
Norman Ornstein, Non-Executive Independent Director | ||
Jeff Wren, Executive Vice President Neurology – Patient Value Unit Head | ||
JeanPierre Kinet, Non-Executive Independent Director | ||
Antje Witte, VP of Investor Relations | ||
Alice Dautry, Independent Director | ||
Sandrine CFA, Ex CFO | ||
Harriet Edelman, Non-Executive Independent Director | ||
Ulf Wiinberg, Independent Director | ||
William Silbey, Exec Counsel | ||
Thomas McKillop, Non-Executive Independent Director | ||
Charl Zyl, Executive Vice President Head of Patient Value Operations, Member of the Executive Committee | ||
France Nivelle, VP Global Communication | ||
Fabrice Enderlin, Executive Vice President - Human Resources & Communication, Member of the Executive Committee | ||
Pierre Gurdjian, Independent Director | ||
Ismail Kola, Chief Scientific Officer, Head of New Medicines Patient Value Unit and Executive VP | ||
Emmanuel Caeymaex, Executive Vice President Immunology - Patient Value Unit Head | ||
Evelyn Bergendal, Non-Executive Vice Chairwoman of the Board | ||
Iris LoewFriedrich, Executive Vice President Chief Medical Officer | ||
CharlesAntoine Janssen, Non-Executive Director | ||
Pr LowFriedrich, Chief VP | ||
Kirsten LundJurgensen, Ex Solutions | ||
Albrecht Graeve, Non-Executive Independent Director | ||
JeanLuc Fleurial, Executive Vice President Chief Talent Officer, Member of the Executive Committee | ||
Alexander Moscho, Executive Vice President Chief Strategy Officer, Member of the Executive Committee |
UCB Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is UCB SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.11 | |||
Return On Asset | 0.0468 | |||
Profit Margin | 0.15 % | |||
Operating Margin | 0.19 % | |||
Current Valuation | 16.62 B | |||
Shares Outstanding | 379.92 M | |||
Price To Earning | 17.55 X | |||
Price To Book | 1.55 X | |||
Price To Sales | 2.54 X | |||
Revenue | 5.78 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.ABBV | AbbVie Inc | |
HBI | Hanesbrands | |
MIDU | Direxion Daily Mid |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UCB SA ADR. Also, note that the market value of any Company could be tightly coupled with the direction of predictive economic indicators such as signals in inflation. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Complementary Tools for UCB Pink Sheet analysis
When running UCB SA's price analysis, check to measure UCB SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy UCB SA is operating at the current time. Most of UCB SA's value examination focuses on studying past and present price action to predict the probability of UCB SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move UCB SA's price. Additionally, you may evaluate how the addition of UCB SA to your portfolios can decrease your overall portfolio volatility.
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |